INBX Overview

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.

Wall Street analysts forecast INBX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INBX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Inhibrx Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased

Inhibrx Biosciences Inc. EPS for the last quarter amounts to -2.28 USD, decreased -19.72

Inhibrx Biosciences Inc (INBX) has 156 emplpoyees as of March 11 2026.

Today INBX has the market capitalization of 1.04B USD.